Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway.
Vaccine. 2012 May 30;30 Suppl 2:B57-62. doi: 10.1016/j.vaccine.2011.12.093.
The development of conjugate vaccines has enabled the prevention and control of Neisseria meningitidis caused by serogroups A, C, W-135 and Y. Vaccines that provide protection against a broad number of serogroup B strains likely will be available soon to enable greater control of meningococcal disease in high income countries. We present an argument for adequate post-marketing surveillance to monitor epidemiological shifts and to provide a context for the safety and reactogenicity of serogroup B vaccines, including the newer recombinant vaccines. We also offer a series of recommendations to address possible concerns about vaccine safety.
结合疫苗的发展使 A、C、W-135 和 Y 血清群脑膜炎奈瑟菌的预防和控制成为可能。针对大量 B 血清群菌株的疫苗可能很快就会上市，从而使高收入国家能够更好地控制脑膜炎球菌病。我们提出了充分的上市后监测的论据，以监测流行病学变化，并为 B 血清群疫苗（包括新型重组疫苗）的安全性和反应原性提供背景。我们还提出了一系列建议，以解决对疫苗安全性的潜在关注。
